Table 2.
Association of NNMT expression with clinicopathological characteristics in 82 breast cancer patients with a chemotherapy efficacy record
| Patient characteristics | n | NNMTh (%) | Pearson’s χ2 | P |
|---|---|---|---|---|
| Total | 82 | 38 (46.3) | ||
|
Age (years) Median = 50 |
≤ 50 (36) | 19 (52.8) | 1.069 | 0.301 |
| > 50 (46) | 36 (41.3) | |||
| ER | Positive (58) | 24 (41.4) | 1.962 | 0.161 |
| Negative (24) | 14 (58.3) | |||
| PR | Positive (53) | 23 (43.4) | 0.523 | 0.470 |
| Negative (29) | 15 (51.7) | |||
| HER-2 | Positive (43) | 22 (51.2) | 1.417 | 0.232 |
| Negative (37) | 14 (37.8) | |||
| Ki-67 | Positive (35) | 15 (42.9) | 0.081 | 0.776 |
| Negative (39) | 18 (46.2) | |||
| Molecular subtype | 3.364 | 0.339 | ||
| Luminal A | 20 | 6 (30.0) | ||
| Luminal B | 42 | 21 (50.0) | ||
| ERBB2 | 13 | 6 (46.2) | ||
| Basal-like | 6 | 4 (66.7) | ||
| TNM | 0.115 | 0.990 | ||
| 0 | 0 | 0 (0) | ||
| I | 27 | 13 (48.1) | ||
| II | 39 | 18 (46.2) | ||
| III | 14 | 6 (42.9) | ||
| IV | 2 | 1 (50.0) | ||
| TNM2 | 0.393 | 0.530 | ||
| 0 + I + II | 63 | 28 (44.4) | ||
| III + IV | 19 | 10 (52.6) | ||
| Primary tumor size | 1.387 | 0.709 | ||
| Tis | 0 | 0 (0) | ||
| T1 | 35 | 18 (51.4) | ||
| T2 | 39 | 16 (41.0) | ||
| T3 | 5 | 3 (60.0) | ||
| T4 | 3 | 1 (33.3) | ||
| Lymph node metastasis | 2.980 | 0.395 | ||
| N0 | 49 | 23 (46.9) | ||
| N1 | 19 | 9 (47.4) | ||
| N2 | 8 | 5 (62.5) | ||
| N3 | 6 | 1 (16.7) | ||
| Distant metastasis | 1.770 | 0.183 | ||
| M0 | 80 | 38 (47.5) | ||
| M1 | 2 | 0 (0) | ||
| Chemotherapy response | 4.807 | 0.028 | ||
| CR+PR | 32 | 10 (31.3) | ||
| SD+PD | 50 | 28 (56.0) | ||
NNMTh NNMT high expression, CR complete response, PR partial response, SD stable disease, PD progressive disease